Glass Pharms, a leading medical cannabis cultivation company based in the UK, has announced the launch of their own-branded range of Cannabis-based products for medicinal use (CBPMs). The products, created in partnership with a UK pharmaceutical manufacturing company, will be available at select pharmacies across the country.
The CBPMs will be made from cannabis flower grown at Glass Pharms’ purpose-built 2.4-hectare facility in Wiltshire. This launch will provide UK clinicians and patients with a wider range of prescribing options that were previously inconsistent. The initial launch will include a High-CBD flower with less than 1% THC, a ratio that has been found to be more effective in treating anxiety according to a recent study by the University of Colorado Boulder.
Glass Pharms CEO, James Duckenfield, stated, “As well as producing High-THC Cannabis flower, we have a commitment to bring CBD-containing medical cannabis flower to the UK market as we believe it gives prescribers options for cannabis-naive patients that would otherwise be missing.” He also emphasized the importance of careful titration of THC content for better outcomes in new users of medical cannabis.
The company will also offer other flowers, such as an entry-level High-THC flower and a high terpene content High-THC flower, with more cultivars to be added to the range in the coming months.
All CBPMs will be manufactured to the new British Pharmacopeia (BP) standard for Cannabis flower, which became legally binding in the UK on July 1st of this year. This marks a significant moment as Cannabis flower is now recognized as a medicine in the British Pharmacopeia for the first time since 1932, when it was removed for prohibitionist reasons.
The flowers are grown in Glass Pharms’ state-of-the-art facility, which operates off-grid and is powered by food waste converted into energy in an adjacent anaerobic digestion plant. This sustainable approach gives the cannabis flower a best-in-class sustainability profile.
For more information about Glass Pharms and their CBPMs, please contact Mark Heley, External Relations at Glass Pharms, at mh@glasspharms.com or 07904 856199.
The study cited by Glass Pharms can be found here: https://cannabishealthnews.co.uk/2024/03/06/study-finds-cbd-can-ease-anxiety-more-effectively-than-thc/
Source: Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study. https://www.liebertpub.com/doi/10.1089/can.2023.0187
Distributed by https://pressat.co.uk/
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.